pharma · Acute Myeloid Leukemia · Relapsed and/or refractory Acute Myeloid Leukemia · KURA
Kura Oncology
Kura Oncology clinical programs — 10 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 12730 High Bluff Dr, Suite 400, San Diego, California 92130, US
- Founded
- 2014
- Employees
- 313
- Programs
- 25
- Drugs
- 14
- Patents
- 132
Kura Oncology projects
10 ClinicalTrials.gov programs sponsored by Kura Oncology.
Kura Oncology has 10 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Cytarabine
Kura Oncology
Acute Myeloid Leukemia
1 trial -
Dexamethasone
Kura Oncology
Lymphoblastic Leukemia
1 trial -
Tipifarnib
Kura Oncology
Thyroid Cancer
1 trial -
Tipifarnib
Kura Oncology
Myelodysplastic Syndromes
1 trial -
Tipifarnib
Kura Oncology
Relapsed or Refractory Peripheral T-Cell Lymphoma
1 trial -
Tipifarnib
Kura Oncology
HNSCC
1 trial -
Tipifarnib
Kura Oncology
HRAS Gene Mutation
1 trial -
Tipifarnib
Kura Oncology
Leukemia, Myelomonocytic, Chronic
1 trial -
Ziftomenib
Kura Oncology
Advanced Malignant Neoplasm
1 trial -
Ziftomenib, Ziftomenib
Kura Oncology
Relapsed and/or refractory Acute Myeloid Leukemia
1 trial
Frequently asked questions
How many clinical projects does Kura Oncology have?
10 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.